Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 5/20 | 0.56 |
| ▸ | CA12 | O43570 | 4/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA6 | P23280 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1603160 | 0.91 | S1PR1 (0.56) | CA9CA12CA1CA6CA7 | |
| SCHEMBL31684366 | 0.85 | S1PR1 (0.45) | CA9CA12CA1CA6CA7 | |
| SCHEMBL22770742 | 0.85 | S1PR1 (0.45) | CA9CA12CA1CA6CA7 | |
| SCHEMBL17897156 | 0.81 | MAOB (0.56) | CA9CA12CA1CA6CA7 | |
| SCHEMBL21860327 | 0.80 | S1PR1 (0.44) | S1PR1S1PR3 | |
| SCHEMBL14369271 | 0.79 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL18838214 | 0.79 | BCHE (0.55) | CA9CA12CA1CA6CA7 | |
| SCHEMBL7273053 | 0.77 | ALDH1A1 (0.54) | CA9CA12CA1CA6CA7 | |
| SCHEMBL12269233 | 0.77 | MAOA (0.47) | CA9CA12CA1CA6CA7 | |
| SCHEMBL3077169 | 0.77 | ALDH1A1 (0.67) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364976-B1 | S1P receptor modulating compounds and use thereof | EPIX PHARM INC (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2364976-B1 | S1P receptor modulating compounds and use thereof | EPIX PHARM INC (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2364976-A1 | S1P receptor modulating compounds and use thereof | EPIX Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2364976-A1 | S1P receptor modulating compounds and use thereof | EPIX Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2007109334-A2 | SIP RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109334-A2 | SIP RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2007-07-26 | — | — | US | disclosed |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2007-07-26 | — | — | US | disclosed |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2007-07-26 | — | — | US | disclosed |
| WO-2007061458-A2 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX DELAWARE, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061458-A2 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX DELAWARE, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | CA9 3737/4885CA12 3761/4885CA1 3759/4885 |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR5, S1PR2 | CA9 3737/4885CA12 3761/4885CA1 3759/4885 |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | CA9 3737/4885CA12 3761/4885CA1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.